Literature DB >> 9174602

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

I Bellinghausen1, G Metz, A H Enk, S Christmann, J Knop, J Saloga.   

Abstract

The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD40, and CD40 ligand (CD40L), cells producing interferon (IFN)-gamma and IL-10 after stimulation with phorbol 12-myristate 13-acetate + ionomycin in the presence of monensin measured by flow cytometry; secretion of IFN-gamma, IL-4, and IL-10 measured by ELISA (IFN-gamma and IL-10 were additionally measured by PCR), and proliferation after stimulation with the respective venom. Significant decreases were observed after VIT for proliferative response to venom and venom + IL-4, IL-4 secretion, Fc epsilon RII, CD40, and CD40L expression. Significant increases were observed after VIT for IFN-gamma concerning the amount secreted and the number of producing cells, and IL-10, IL-10 was mainly produced by CD4+ cells that were negative for IFN-gamma, but some double-positive (IL-10 and IFN-gamma) cells were always detected. Addition of blocking anti-IL-10 antibodies, but not isotype control antibodies, prevented down-regulation of proliferation (but not IL-4 secretion) and further enhanced IFN-gamma secretion after VIT. These data indicate that in insect venom allergic subjects, VIT not only induces a rapid shift in cytokine expression from Th2 to Th1 cytokines, but also leads to induction of the immunosuppressive cytokine IL-10, which may be important for the limitation of potentially harmful allergen-specific Th1 responses. The described changes in cytokine expression may be responsible for subsequent increases in allergen-specific IgG and decreases in IgE production, as well as suppressive activity observed in earlier studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174602     DOI: 10.1002/eji.1830270513

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  47 in total

Review 1.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  TGF-beta-mediated control of allergen-specific T-cell responses.

Authors:  Carsten B Schmidt-Weber; Steffen Kunzmann; Kurt Blaser
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

Review 3.  Tolerizing allergic responses in the lung.

Authors:  C M Lloyd; J R Murdoch
Journal:  Mucosal Immunol       Date:  2010-05-26       Impact factor: 7.313

4.  Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study.

Authors:  Julie Wang; Sangita P Patil; Nan Yang; Jimmy Ko; Joohee Lee; Sally Noone; Hugh A Sampson; Xiu-Min Li
Journal:  Ann Allergy Asthma Immunol       Date:  2010-07       Impact factor: 6.347

5.  High-dose allergen exposure leads to tolerance.

Authors:  Judith A Woodfolk
Journal:  Clin Rev Allergy Immunol       Date:  2005-02       Impact factor: 8.667

Review 6.  Regulatory T cells in human disease and their potential for therapeutic manipulation.

Authors:  Leonie S Taams; Donald B Palmer; Arne N Akbar; Douglas S Robinson; Zarin Brown; Catherine M Hawrylowicz
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 7.  [Mechanisms of specific immunotherapy].

Authors:  I Bellinghausen; J Knop; J Saloga
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

8.  Adjuvant effects of aluminium hydroxide-adsorbed allergens and allergoids - differences in vivo and in vitro.

Authors:  B Heydenreich; I Bellinghausen; L Lund; H Henmar; G Lund; P Adler Würtzen; J Saloga
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 9.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

10.  Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor.

Authors:  Iris Bellinghausen; Bettina König; Ingo Böttcher; Jürgen Knop; Joachim Saloga
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.